The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Natural Products and Derivatives Affecting Neurotransmission Relevant to Alzheimer’s and Parkinson’s Disease
Abstract
The two major neurodegenerative diseases Alzheimer's disease (AD) and Parkinson's disease (PD) are characterised by low levels in the brain of the neurotransmitters acetylcholine (ACh) and dopamine (DA), respectively. Clinical treatment of these two conditions is palliative and relies, in most cases, on improving stimulation at the relevant receptors by either increasing levels of the endogenous neurotransmitter or by the use of substances which have a similar agonist response. Natural products continue to provide useful drugs in their own right but also provide templates for the development of other compounds. The major advances in the treatment of AD have been the use of acetylcholinesterase inhibitors such as galantamine, huperzine A, physostigmine and its derivatives to increase the levels of ACh rather than the use of cholinergic compounds, although compounds with nicotinic properties have attracted some interest. In contrast, the treatment of PD has relied on the elevation of DA levels by use of L-DOPA, its precursor, and by the administration of dopaminergic agonists, especially the ergot alkaloid derivatives. The use of inhibitors of enzymes that cause breakdown of DA is an avenue which is being explored. As well as the major natural products of clinical interest, the paper discusses the chemistry, activity and usage of the constituents of plants used in traditional medicine for the treatment of diseases presenting symptoms similar to those characteristic for Alzheimer's or Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Raskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P., & Damaraju, C. V. (2004) · Archives of Neurology · doi:10.1001/archneur.61.2.252 · Cited by 167
Bhattacharya, S. K., Kumar, A., & Ghosal, S. (1995) · Phytotherapy Research · doi:10.1002/ptr.2650090206 · Cited by 112
Parihar, M. S., & Hemnani, T. (2003) · Journal of Biosciences · doi:10.1007/bf02970142 · Cited by 102
Whitehouse, P. J., & Kalaria, R. N. (1995) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199501002-00002 · Cited by 79
Cited by
Acetylcholinesterase inhibitors from plants and fungi
Houghton, P. J., Ren, Y., & Howes, M.-J. (2006) · Natural Product Reports · doi:10.1039/b508966m · Cited by 584
Self-citationPlants traditionally used in age related brain disorders—A survey of ethnobotanical literature
Adams, M., Gmünder, F., & Hamburger, M. (2007) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2007.07.016 · Cited by 327
Plants-derived neuroprotective agents: cutting the cycle of cell death through multiple mechanisms
Elufioye, T. O., Berida, T. I., & Habtemariam, S. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/3574012 · Cited by 107
Orhan, G., Orhan, I., Subutay-Oztekin, N., Ak, F., & Sener, B. (2009) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488909787002582 · Cited by 90
Traditional used Plants against Cognitive Decline and Alzheimer Disease
Eckert, G. P. (2010) · Frontiers in Pharmacology · doi:10.3389/fphar.2010.00138 · Cited by 47
Metadata
- Authors
- Houghton, P. J., & Howes, M.-J.
- Venue
- Neurosignals
- Publisher
- S. Karger AG
- Published
- 2005
- Volume
- 14
- Issue
- 1-2
- Pages
- 6-22
- ISSN
- 1424-862X (ISSN-L)
- 1424-8638
- OpenAlex
- W1992123323
- Cited by
- 227
- References
- 5
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Natural Products and Derivatives Affecting Neurotransmission Relevant to Alzheimer’s and Parkinson’s Disease. https://app.cochat.ai/papers/10.1159/000085382
- The paper
- Houghton, P. J., & Howes, M.-J. (2005). Natural Products and Derivatives Affecting Neurotransmission Relevant to Alzheimer’s and Parkinson’s Disease. Neurosignals. https://doi.org/10.1159/000085382
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.